Cure for gluten intolerance feasible with synthetic enzymes

intestines
Celiac disease is a serious genetic autoimmune disorder where the small intestine is hypersensitive to gluton. Thus, this condition leads to difficulty in digesting food.

Research to create a cure for celiac disease that started [at the University of Washington] is now moving to the next level with a start-up company.

“This has the potential to be used orally to break down gluten before it can reach the intestines,” said Ingrid Swanson Pultz, Ph.D., who co-founded PVP Biologics.

When this work started [in 2011], Pultz said, the students treated it almost like a video game — a competition to build the best synthetic protein to break down gluten.

“It worked. It didn’t work extremely well, but it worked,” said Pultz. So well in fact, that the students’ prototype won a global competition that fall….

“And we further developed the enzyme, and now we have something that’s really, really powerful,” she said.

Grant money only goes so far for research, so now the university welcomes Pultz and her partners in PVP Biologics to Fluke Hall, which is designed specifically for these types of startups.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Potential cure for celiac advances at the UW

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
Picture1-14
When superbugs threaten vulnerable children: Can AI help solve antibiotic resistance?
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.